Cargando…
Molnupiravir plus usual care versus usual care alone as early treatment for adults with COVID-19 at increased risk of adverse outcomes (PANORAMIC): an open-label, platform-adaptive randomised controlled trial
BACKGROUND: The safety, effectiveness, and cost-effectiveness of molnupiravir, an oral antiviral medication for SARS-CoV-2, has not been established in vaccinated patients in the community at increased risk of morbidity and mortality from COVID-19. We aimed to establish whether the addition of molnu...
Ejemplares similares
-
Platform adaptive trial of novel antivirals for early treatment of COVID-19 In the community (PANORAMIC): protocol for a randomised, controlled, open-label, adaptive platform trial of community novel antiviral treatment of COVID-19 in people at increased risk of more severe disease
por: Gbinigie, Oghenekome, et al.
Publicado: (2023) -
Doxycycline for community treatment of suspected COVID-19 in people at high risk of adverse outcomes in the UK (PRINCIPLE): a randomised, controlled, open-label, adaptive platform trial
por: Butler, Christopher C, et al.
Publicado: (2021) -
Colchicine for COVID-19 in the community (PRINCIPLE): a randomised, controlled, adaptive platform trial
por: Dorward, Jienchi, et al.
Publicado: (2022) -
Trimethoprim is associated with a greater risk of acute kidney injury and hyperkalaemia in older adults compared with other antibiotics used to treat UTIs
por: Gbinigie, Oghenekome
Publicado: (2018) -
The usual suspects
por: Petsko, Gregory A
Publicado: (2003)